Table 1. Clinicopathological features.
| Clinicopathological features | N (%) |
|---|---|
| Age1 median (range) | 67 years (23–91) |
| Gender | |
| Female | 59 (51.8%) |
| Male | 55 (48.3%) |
| Primary tumor | |
| Melanoma type | |
| Cutaneous | 90 (79.0%) |
| Ocular | 11 (9.7%) |
| Mucosal | 1 (0.9%) |
| Unknown primary site | 12 (10.5%) |
| Initial T | |
| T1-2 | 32/96 (33.3%) |
| T3-4 | 64/96 (66.7%) |
| Breslow's depth2 mean (±sd) | 4.2 mm (±5.9) |
| Initial N | |
| N0 | 38/91 (41.8%) |
| N1-3 | 53/91 (58.2%) |
| Initial M | |
| M0 | 82/98 (83.7%) |
| M1 | 16/98 (16.3%) |
| Mutation status | |
| BRAF mutated | 41/77 (53.6%) |
| NRAS mutated | 13/35 (37.1%) |
| cKIT mutated | 1/19 (5.3%) |
| Metastatic lesion | |
| Clinical stage1 | |
| Stage III | 41 (36.0%) |
| Stage IV | 73 (64.0%) |
| Biopsy sites | |
| Lymph node | 46 (40.4%) |
| Skin and subcutaneous tissue | 24 (21.1%) |
| Lung | 18 (15.8%) |
| Central Nervous System (CNS) | 9 (7.9%) |
| Liver | 8 (7.0%) |
| Gastrointestinal tract | 4 (3.5%) |
| Other (bone, breast, peritoneum, thyroid and spleen) | 5 (4.4%) |
| Previous treatments | |
| Treatment naïve | 73/113 (64.6%) |
| Previously treated | 40/113 (35.4%) |
| Treatments received | |
| Radiation therapy | 27/40 (67.5%) |
| Chemotherapy | 12/40 (30.0%) |
| Targeted therapy | 11/40 (27.5%) |
| Immunotherapy | 21/40 (52.5%) |
| Follow-up | Mean (±sd) |
| Time from diagnosis to biopsy | 48.1 months (±60.6) |
| Time from diagnosis to death/latest news | 66.3 months (±63.6) |
| Time from biopsy to death/latest news | 17.6 months (±16.3) |
| Deaths from any cause N (%) | 40 (35.1%) |
1. At the time of sample collection. 2. Percentage based on the total number of patients with known Breslow's depth (N = 90). The 24 other patients had ocular, mucosal or unknown primary site melanoma.